About dexrazoxane hydrochloride
Anthracycline cardioprotective agent
Used for
- Reduces heart damage from doxorubicin in adults with advanced or metastatic breast cancer after substantial prior treatment.
- Treats severe tissue injury from accidental leakage of certain anthracycline chemotherapy drugs.
Usual adult dose
For doxorubicin heart protection: 10 times the doxorubicin dose by infusion before each dose. For anthracycline leakage: 1,000 mg/m² on days 1 and 2, then 500 mg/m² on day 3.
Common side effects
- Nausea and vomiting
- Low blood-cell counts and increased infection risk
- Injection-site pain or inflammation
- Fatigue
Important warnings
- May cause serious bone marrow suppression; blood counts require monitoring.
- Heart protection use is limited to specific adults receiving doxorubicin.
- Leakage treatment should begin as soon as possible, within six hours.
- Dose reduction may be needed with impaired kidney function.
Pregnancy
May harm an unborn baby. Avoid during pregnancy unless clearly necessary; effective contraception is advised during treatment.
Breastfeeding
Breastfeeding is not recommended during treatment and for two weeks after the final dose.
Interactions
- Other chemotherapy can increase bone marrow suppression.
- Dexrazoxane may reduce some chemotherapy effects when used outside approved circumstances.
AI-generated from general medical knowledge, not from this product's official leaflet. It may be incomplete or out of date. Not medical advice — ask a pharmacist or doctor before making any decision.